Evidence map›Paper›PMID 34222726›Full record

ReviewJACC. Basic to translational science2021

B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.

Tanyaporn Pattarabanjird, Cynthia Li, Coleen McNamara

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. Basic to translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tanyaporn PattarabanjirdCardiovascular Research Center, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Cynthia LiCardiovascular Research Center, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Coleen McNamaraCardiovascular Research Center, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
University of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because atherosclerotic cardiovascular disease is a leading cause of death worldwide, understanding inflammatory processes underpinning its pathology is critical. B cells have been implicated as a key immune cell type in regulating atherosclerosis. B-cell effects, mediated by antibodies and cytokines, are subset specific. In this review, we focus on elaborating mechanisms underlying subtype-specific roles of B cells in atherosclerosis and discuss available human data implicating B cells in atherosclerosis. We further discuss potential B cell-linked therapeutic approaches, including immunization and B cell-targeted biologics. Given recent evidence strongly supporting a role for B cells in human atherosclerosis and the expansion of immunomodulatory agents that affect B-cell biology in clinical use and clinical trials for other disorders, it is important that the cardiovascular field be cognizant of potential beneficial or untoward effects of modulating B-cell activity on atherosclerosis.

Indexed as

ApoE, apolipoprotein EAPRIL, A proliferation−inducing ligandatherosclerosisBAFF, B-cell–activating factorBAFFR, B-cell–activating factor receptorB-cellBCMA, B-cell maturation antigenBCR, B-cell receptorBreg, regulatory B cellCAD, coronary artery diseaseCTLA4, cytotoxic T-lymphocyte–associated protein 4CVD, cardiovascular diseaseCXCR4, C-X-C motif chemokine receptor 4GC, germinal centerGITR, glucocorticoid-induced tumor necrosis factor receptor–related proteinGITRL, glucocorticoid-induced tumor necrosis factor receptor–related protein ligandGM-CSF, granulocyte-macrophage colony–stimulating factorICI, immune checkpoint inhibitorIFN, interferonIL, interleukinimmunoglobulinsIVUS, intravascular ultrasoundLDL, low-density lipoproteinLDLR, low-density lipoprotein receptormAb, monoclonal antibodyMDA-LDL, malondialdehyde-modified low-density lipoproteinMI, myocardial infarctionOSE, oxidation-specific epitopeOxLDL, oxidized low-density lipoproteinPC, phosphorylcholinePD-1, programmed cell death protein 1PDL1, programmed death ligand 1PD-L2, programmed death ligand 2RA, rheumatoid arthritisSLE, systemic lupus erythematosusTACI, transmembrane activator and CAML interactorTNF, tumor necrosis factorTreg, regulatory T cell

Identifiers

PMID34222726
PMCPMC8246059
OpenAlexW3176962030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.